Turning the Tide Against Cancer: NCCS CEO Presents Survivor Perspective on Incentive Structures and Innovation

We have a lot of bad incentives built into our system, says @sfuldnasso at #T3Cancer
— ThinkWellPoint (@ThinkWellPoint) 

“We need truth telling so patients understand the full influences on their care” Shelley Fuld Nasso @CancerAdvocacy #T3Cancer — CancerSupportCm (@CancerSupportCm) 

We need to ask patients what’s important to them in order to match their goals & priorities for delivery reform – @sfuldnasso at #T3Cancer — ThinkWellPoint (@ThinkWellPoint)

NCCS CEO Shelley Fuld Nasso spoke at the 2014 Turning the Tide Against Cancer Conference in Washington, DC yesterday in a session addressing the role of payment reforms in supporting innovative cancer care. The spotlight session examined incentive structures and their impact on innovation. This issue has been at the forefront of NCCS’ policy priorities as we advocate for a cancer care system that is evidence-based, quality-driven, patient-focused, and affordable and accessible to all.  NCCS recently offered comments to the Centers for Medicare and Medicaid Innovation on its proposed Oncology Care Model, an episode-based payment model that emphasizes care planning and coordination and cancer care system transformation. Shelley has also written a post as part of our “What Caught Our Eye This Week” series in response to two America Tonight segments that delved into the cost of cancer care and delivering care differently to reduce costs and improve quality for patients.

The conference, organized by the Personalized Medicine Coalition the American Association for Cancer Research, and Feinstein Kean Healthcare, convened leaders in health policy to continue the ongoing dialogue around potential policy solutions that align with scientific advances and support innovation, while addressing the issue of rising health care costs.

The conference also engaged the cancer community through the #T3cancer hashtag on Twitter, and several of these tweets resonated with us:

 

Dr. Stephen Eck: The value of a medicine goes beyond what’s learned through clinical trials, value evolves over time #T3Cancer — PACE Network USA (@PACENetworkUSA) October 9, 2014

Access to quality, coordinated medical care is still a huge problem in the US. @sulekiajaouad #t3cancer — Prevent Cancer (@preventcancer) October 9, 2014

Abernathy: biggest predictor of patients completing PRO survey is doc acknowledging having reviewed it. #T3Cancer — Shelley Fuld Nasso (@sfuldnasso) October 9, 2014

Takeaway from #T3Cancer: What does value mean to the patient? -Amy Miller of @newsfrompmc — ThinkWellPoint (@ThinkWellPoint) October 9, 2014